Figure 4.
![Comparison of rwOS after applying IPTW between patients with high- and non–high-risk CLL/SLL using an alternative definition of high risk [presence of del(17p) or unmutated IGHV only], and in Medicare subgroups.](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/9/15/10.1182_bloodadvances.2024015417/1/blooda_adv-2024-015417-gr4.jpeg?Expires=1756607900&Signature=oqiD83PnX4iAqVS2g5G~ETo-pwaOCLIuhtYTduQyqj3MSnCRaWgbmOqumfXsrJP3Qe~h2O84TqHE6sgjVMOP2YkG1pvjU66av8e47mQNV~1rSOM5AcYCpy9gExAdbeVgcjd6Gz~VPBsxViGSREAhGD6StIDTCRVVmtO-hgSjcpDLidEukHqYvHBGTf1VYZllWtf~Pn-oHQ45P-0aeDJsn9fFH6bkXs~vvLSqOAGtPu5xsI4uQ8SEE0MbUIKdWvuG3MEZHV44XKk6REAEh1Q4g9muD0YVUoYLR2kU69uX~hVFw7uDlsS91UcQGafGX4CKtSK9xjvFwm15QPYfEZ~jlQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Comparison of rwOS after applying IPTW between patients with high- and non–high-risk CLL/SLL using an alternative definition of high risk [presence of del(17p) or unmutated IGHV only], and in Medicare subgroups.
Comparison of rwOS after applying IPTW between patients with high- and non–high-risk CLL/SLL using an alternative definition of high risk [presence of del(17p) or unmutated IGHV only], and in Medicare subgroups.
